Immunome reports FY 2024 net loss of $293M; cash runway into 2027, pipeline milestones ahead

Immunome Inc.

Net loss $293.0M for FY 2024; cash & equivalents $217.3M at Dec 31, 2024.
January 2025 upsized offering raised $172.5M gross; cash runway now extends into 2027.
Phase 3 RINGSIDE topline data for varegacestat in desmoid tumors expected H2 2025.
Phase 1 of IM-1021 (ROR1 ADC) dosed first patient Feb 2025; IND for IM-3050 (FAP radioligand) submitted March 2025.
Preclinical ADCs IM-1617, IM-1340, IM-1335 in IND-enabling work; additional discovery programs ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.